hemolytic

Iptacopan hydrochloride (LNP023 hydrochloride) is a small-molecule inhibitor and a complement factor B inhibitor (IC50 = 10 nM, KD = 7.9 nM) with high selectivity, oral activity, and cell permeability, used for the treatment of complement-mediated diseases including paroxysmal nocturnal hemoglobinuria, IgA nephropathy, and C3 glomerulopathy.

Prosaikogenin F ((2R,3R,4S,5R,6R)-2-{[(1S,2R,4S,5R,8R,9S,10R,13S,14R,17S,18R)-2-hydroxy-9-(hydroxymethyl)-4,5,9,13,20,20-hexamethyl-24-oxahexacyclo[15.5.2.01,1?.0?,1?.0?,1?.0?,13]tetracos-15-en-10-yl]oxy}-6-methyloxane-3,4,5-triol) is a natural product with anticancer and hemolytic properties [1].

Streptokinase, an enzyme from Streptococcus hemolyticus (EC 3.4.99.0), is secreted by various streptococci. It binds to and activates human plasminogen. The complex formed between streptokinase and human plasminogen can activate additional unbound plasminogen by cleaving specific bonds, resulting in the production of plasmin.

Questin is an antimicrobial agent derived from Aspergillus florescens with an antimicrobial activity profile that inhibits V. harveyi, V. anguillarum, V. cholerae and V. parahemolyticus with MIC values of 31.25 µg/mL, 62.5 µg/mL, 62.5 µg/mL and 125 µg/mL, respectively. Questin has good potential to inhibit AChE, BChE and BACE1 and may be used in the development of drugs for the treatment or prevention of Alzheimer's disease.

Antimicrobial agent-22 (THI 6c) is a broad-spectrum, multi-target antibacterial with rapid bactericidal efficacy, effective anti-biofilm activity, and low cytotoxicity and hemolytic properties [1].

Surfactin is a potent cyclic lipopeptide biosurfactants that mediates flux of mono-and divalent cations, such as calcium, across lipid bilayer membranes, with anti-bacterial, anti-fungal, antimycoplasma and hemolytic effects.

Phenazopyridine hydrochloride (Pyridium) is used orally as a urinary tract analgesic. Side effects of phenazopyridine hydrochloride administration can include nausea, interference with the oxygen-carrying capacity of red blood cells (methemoglobinemia), hemolytic anemia as well as renal and hepatic toxicity. It is reasonably anticipated to be a human carcinogen.

Tafenoquine (WR 238605) is an antimalarial prophylactic agent with schizonticidal activity, useful in hemolytic anemia research.

Taribavirin hydrochloride is an orally active inosine monophosphate dehydrogenase inhibitor designed to concentrate within the liver to target HCV-infected hepatocytes, while minimizing distribution within red blood cells and the development of hemolytic anemia [2].

Taribavirin is an orally active inosine monophosphate dehydrogenase inhibitor designed to concentrate within the liver to target HCV-infected hepatocytes, while minimizing distribution within red blood cells (RBCs) and thereby reducing the risk of developing hemolytic anemia.

Antibacterialagent 244 is a compound that exhibits broad-spectrum antibacterial activity and oral efficacy, primarily targeting Gram-positive bacteria with a minimum inhibitory concentration (MIC) of 1-4 μg/mL. It possesses low hemolytic toxicity (HC50 of 111.6 μg/mL). The mode of action for Antibacterialagent 244 involves disrupting the bacterial transmembrane potential and increasing membrane permeability, which leads to the leakage of cellular contents such as DNA and proteins, ultimately causing bacterial death. This compound is useful in research related to infections caused by Gram-positive bacteria.

Benzobarbital is utilized in the treatment of convulsive forms of epilepsy, hemolytic disease of the newborn, and insomnia.

LB 11058 is a novel injectable cephalosporin featuring a C-3 pyridyl-substituted vinyl sulfide and a C-7 2-amino-5-chloro-1,3-thiazole group. This compound exhibits exceptional activity against Streptococcus pneumoniae and demonstrates similar efficacy against β-hemolytic streptococci. The inhibition pattern for LB 11058 with S. aureus is consistent, as all isolates are inhibited under this pattern.

Antibacterialagent 256 (Compound C09) is an inhibitor of Type I signal peptidase (SPase I). It targets Gram-positive bacteria, effectively inhibiting S. aureus ATCC 29213, E. faecium QF31, E. faecalis SF23-1, and S. suis P1/7, with MIC values ranging from 1-16 μg/mL. In cancer cells HEp-2 and Caco-2, Antibacterialagent 256 exhibits cytotoxicity with CC50 values of 14.65 μg/mL and 21.93 μg/mL, respectively. Additionally, it shows hemolytic activity on mouse red blood cells with an HC50 of 13.29 μg/mL and can improve MRSA skin infections in mouse models.

Antibacterialagent 258 (Compound 11e) is an antimicrobial agent capable of disrupting bacterial cell membranes and inhibiting various Gram-positive bacteria, with a MIC of 1-2 μg/mL against Staphylococcus aureus. It exhibits low hemolytic activity and cytotoxicity, and demonstrates anti-infective properties in mouse models.

FtsZ-IN-12 (Compound 16e) is an inhibitor of filamentous temperature-sensitive mutant Z (FtsZ) that promotes the polymerization of the FtsZ protein and suppresses its GTPase activity, thus disrupting the bacterial cell division process. This compound exhibits broad-spectrum antibacterial activity, effectively inhibiting B. subtilis ATCC 9372, B. pumilus CMCC 63202, S. aureus ATCC 25923, E. coli BW25113, and A. baumannii ATCC 19606 with MIC values ranging from 0.062-1 µg/mL. Additionally, FtsZ-IN-12 can inhibit biofilm formation and eliminate mature biofilms. It possesses bactericidal properties and shows no hemolytic toxicity to mammalian red blood cells at a dosage of 15 mg/kg.

ROS inducer 8 (Compound 11g) acts as an inhibitor of glutathione (GSH) and promotes the accumulation of reactive oxygen species (ROS) in Enterococcus faecalis, exhibiting antibacterial properties. It is capable of disrupting biofilms and inhibiting S. aureus and E. faecalis with minimum inhibitory concentrations (MICs) of 8 μg/mL and 2 μg/mL, respectively, demonstrating a post-antibiotic effect. Additionally, ROS inducer 8 shows low hemolytic toxicity on sheep red blood cells with an HC50 greater than 1280 μg/mL.

XT17 is an anthrone compound with broad-spectrum antibacterial activity, exerting its effects by disrupting the cell wall and inhibiting DNA synthesis. It demonstrates weak hemolytic activity, low cytotoxicity to mammalian cell lines, and a low rate of resistance development. Additionally, XT17 shows in vivo efficacy in a mouse corneal infection model induced by Staphylococcus aureus or Pseudomonas aeruginosa. Further docking studies confirm that XT17 forms a stable complex with bacterial gyrase. XT17 is suitable for research in the field of anti-infective agents.

Antibacterialagent 217 (Compound 24) is a non-cytotoxic and non-hemolytic antibacterial agent with moderate activity. It inhibits the growth of Staphylococcus aureus strains with a minimum inhibitory concentration (MIC) of 32 μg/mL. Additionally, Antibacterialagent 217 moderately suppresses the growth of Staphylococcus epidermidis.

Anti-infective agent 12 (Compound A09) is a competitive inhibitor of type I signal peptidase (SPase I) with an IC50 of 4.475 μM and a Kd of 16.3 μM. It disrupts bacterial membranes and has biofilm-clearing capabilities. This agent exhibits potent bactericidal activity against Gram-positive bacteria, with MIC values of 4, 4, 8, and 8 μg/mL for Staphylococcus aureus, Enterococcus faecium, Enterococcus faecalis, and Streptococcus suis, respectively. Despite its effectiveness against multidrug-resistant strains, it shows weaker activity against Gram-negative bacteria, such as Escherichia coli and Salmonella spp. (MIC > 64 μg/mL). Anti-infective agent 12 has low hemolytic properties and demonstrates significant efficacy in mouse skin infection models. It reduces the risk of resistance emerging from single-target mutations and can be used in the study of multidrug-resistant Gram-positive bacterial infections.

Anti-MRSA agent 36 (Compound III13) is a potent antibacterial compound with significant anti-MRSA activity (MIC = 1 μg/mL). It targets phosphatidylglycerol (PG) on bacterial membranes, disrupting membrane integrity, leading to DNA leakage and increased ROS. The agent offers advantages such as low cytotoxicity, low hemolytic activity, reduced likelihood of inducing resistance, and excellent plasma stability. Anti-MRSA agent 36 is applicable for research in skin abscess and systemic infection models.

Lug-15 is a rapid bactericide exhibiting strong antibacterial activity against various Gram-positive and Gram-negative bacteria, including drug-resistant strains. It swiftly eradicates bacteria primarily by disrupting bacterial cell membranes and has a very low tendency to induce resistance. Lug-15 shows low hemolytic toxicity and demonstrates significant efficacy in various infection models. It can be used for research on combating multidrug-resistant infections.

LP-03 is an antibacterial agent that exhibits selective activity against methicillin-resistant Staphylococcus aureus (MRSA) with a minimum inhibitory concentration (MIC) of 6.2 μM. It inhibits biofilm formation but is ineffective at removing established biofilms. LP-03 enhances membrane permeability, disrupting the membrane structure of MRSA cells without causing significant membrane depolarization. It shows no hemolytic toxicity and demonstrates low cytotoxicity to mammalian cells. This compound can be utilized for studying MRSA infections.

Antibacterialagent 302 is an antibacterial compound with strong and broad-spectrum activity. It exhibits minimal hemolytic toxicity and cytotoxicity, and has a low tendency to induce resistance. Its mechanism of action involves disrupting the integrity of bacterial cell membranes. Antibacterialagent 302 is applicable for research into bacterial keratitis.